InvestorsHub Logo
Followers 0
Posts 72
Boards Moderated 0
Alias Born 04/28/2021

Re: None

Wednesday, 02/01/2023 7:39:49 AM

Wednesday, February 01, 2023 7:39:49 AM

Post# of 224
Cybin Announces Approval of First-in-Human Dosing of its Proprietary DMT Molecule CYB004

- Marks first ever trial to evaluate deuterated DMT in humans –

- Based on preclinical studies CYB004 demonstrated superior bioavailability compared to IV DMT which may support less invasive dosing methods -

- CYB004 is a patented proprietary molecule protected through 2041 -

https://ir.cybin.com/investors/news/news-details/2023/Cybin-Announces-Approval-of-First-in-Human-Dosing-of-its-Proprietary-DMT-Molecule-CYB004/default.aspx
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYBN News